Key Points
- Daniel Allen Gold sold 777,332 ROIV shares on Dec. 17 at an average of $23.07 for $17.93M, cutting his stake by 4.54% to 16,353,113 shares valued at about $377.27M.
- The director also sold 917,282 shares on Dec. 16 ($21.13M) and 1.3M shares on Nov. 19 ($26.30M), totaling ~2.99M shares and roughly $65.36M in proceeds, indicating notable insider selling.
- Roivant trades near its 52-week high ($23.47) with a $15.15B market cap, 64.76% institutional ownership, and a consensus analyst rating of Moderate Buy with a $25.19 price target.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Daniel Allen Gold sold 777,332 shares of the company's stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $23.07, for a total transaction of $17,933,049.24. Following the completion of the sale, the director directly owned 16,353,113 shares in the company, valued at $377,266,316.91. This trade represents a 4.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Daniel Allen Gold also recently made the following trade(s):
- On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The shares were sold at an average price of $23.04, for a total transaction of $21,134,177.28.
- On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.23, for a total value of $26,299,000.00.
Roivant Sciences Stock Performance
NASDAQ ROIV opened at $21.79 on Friday. The firm has a market capitalization of $15.15 billion, a P/E ratio of -38.91 and a beta of 1.22. The stock has a 50-day simple moving average of $19.88 and a two-hundred day simple moving average of $14.99. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $23.47.
Hedge Funds Weigh In On Roivant Sciences
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp boosted its stake in shares of Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company's stock worth $25,000 after acquiring an additional 1,148 shares during the last quarter. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after purchasing an additional 583 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock worth $28,000 after buying an additional 543 shares in the last quarter. CWM LLC raised its position in shares of Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company's stock valued at $34,000 after buying an additional 920 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd boosted its position in Roivant Sciences by 75.8% during the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company's stock worth $67,000 after acquiring an additional 1,900 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the company. JPMorgan Chase & Co. upped their price objective on Roivant Sciences from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Thursday, September 18th. The Goldman Sachs Group raised their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a "buy" rating in a research report on Monday. Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of Roivant Sciences in a research report on Thursday. Bank of America raised their target price on Roivant Sciences from $12.00 to $16.50 and gave the company a "neutral" rating in a research report on Thursday, September 18th. Finally, Weiss Ratings raised Roivant Sciences from a "sell (d+)" rating to a "hold (c-)" rating in a report on Saturday, October 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.19.
Check Out Our Latest Stock Analysis on ROIV
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
